|
 The China Food and Drug Administration said it was investigating
Hebei Yongfeng Yaoye, a subsidiary of Hong Kong-listed CSPC
Pharmaceutical Group, as well as Gansu Dadeli Pharmaceutical and
Guizhou Shouxian Pharmaceutical.
The firms were suspected of using illegal production methods and had
been ordered to recall their products, the watchdog said in a
statement on Monday.
China is pushing an ambitious program of healthcare reforms to
improve its home-made medicines, and has vowed to crack down on poor
quality drugs.
The problem was highlighted by a recent scandal over almost $90
million worth of illegal vaccines that were suspected of being sold
in dozens of provinces around the country.
A woman who answered the phone at Hebei Yongfeng Yaoye declined to
comment on the investigation. Calls to Guizhou Shouxian
Pharmaceutical and Gansu Dadeli Pharmaceutical went unanswered.
(Reporting by Brenda Goh; Editing by Stephen Coates)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
[to top of second column] |
